ArticleNeuro-oncology advances
Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trial.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Linking early and late endpoints in adjuvant immunotherapy trials: an evaluation of multiple clinical outcomes.The oncologist · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioblastoma confers a bleak prognosis, with median survival of less than a year. This trial evaluated whether addition of the CTLA-4 immune checkpoint inhibitor ipilimumab to standard therapy improves survival in patients with recently diagnosed glioblastoma. Methods: Ipi-Glio was a stratified randomized, open-label, multicenter, academic phase II study. Patients with recently diagnosed de novo glioblastoma following completion of chemoradiotherapy were randomized 2:1 to ipilimumab + temozolomide (Arm A) vs temozolomide alone (Arm B), stratified to extent of surgery and MGMT promotor methylation. Primary endpoint was overall survival. Secondary endpoints included progression-free survival at 18 months, overall survival at 3 years, and toxicity (≥Grade 3). Results: One hundred nineteen patients were randomized (79 to Arm A, 40 to Arm B). Patient characteristics (Arm A vs B): median age 57 vs 49 years; male sex 70 vs 65%, gross total resection 61 vs 60%, tumor MGMT promotor methylation 39 vs 40%. Median overall survival was 18 months (60% CI 16.0, 23.9) in Arm A vs 23.0 months (17.3, 26.4) in Arm B (adjusted HR 1.09, 60% CI 0.86,1.38, one-sided Conclusions: No benefit was observed with the addition of ipilimumab to temozolomide in patients with recently diagnosed glioblastoma following chemoradiotherapy. This study does not support further investigation of this regimen in this setting. Trial Registration: ISRCTN84434175 (www.isrctn.com/ISRCTN84434175).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.